Log in to search using one of your social media accounts:


Cytokinetics ALS Drug Fails

Cytokinetics, a biotechnology company, had hoped that by focusing on improving the function of muscle, not nerves, it could have an impact on lung function in patients with amyotrophic lateral sclerosis, popularly known as Lou Gehrig's disease, a nerve-destroying disorder. It didn't work.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Authors: Liu J, Wang LN Abstract Neurodegenerative movement disorders mainly include Parkinson's disease, atypical parkinsonisms, Huntington disease, and hereditary ataxia. Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis. The neuroprotective effects of riluzole have been observed in experimental models of neurodegenerative movement disorders. In this paper, we aimed to systematically analyze the efficacy and safety of riluzole for patients with neurodegenerative movement disorder. We searched the electronic databases such as PubMed, EMBASE, CINAHL, Cochran...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
The cover image, by Sali M. K. Farhan et al., is based on the Research Article OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia, DOI: 10.1002/ajmg.b.32606.
Source: American Journal of Medical Genetics Part B: Neuropsychiatric Genetics - Category: Genetics & Stem Cells Authors: Tags: COVER IMAGE Source Type: research
Source: Journal of Magnetic Resonance Imaging - Category: Radiology Authors: Tags: Cover Image Source Type: research
Antioxidants&Redox Signaling , Vol. 0, No. 0.
Source: Antioxidants and Redox Signaling - Category: Research Authors: Source Type: research
Condition:   Amyotrophic Lateral Sclerosis Intervention:   Dietary Supplement: Blood sample and environmental survey Sponsor:   Centre Hospitalier Universitaire de Pointe-a-Pitre Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Background: To prospectively evaluate the progression of cognitive-behavioral function in amyotrophic lateral sclerosis (ALS) and examine the association of cognitive-behavioral deficits with disease progression, patient quality of life (QOL), and caregiver burden. Methods: We evaluated cognitive-behavioral function using the Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen at enrollment and after 7 months in a cohort of patients with ALS. Paired t tests were used to evaluate the change in the 2 assessments. Linear regression and Kruskal-Wallis tests were applied to investigate how initial cognitive or behavioral...
Source: Neurology Clinical Practice - Category: Neurology Authors: Tags: Quality of life, Amyotrophic lateral sclerosis, Frontotemporal dementia, Assessment of cognitive disorders/dementia Research Source Type: research
Chronic traumatic encephalopathy (CTE) is the neurodegenerative disease of the moment, made famous by the violent and untimely deaths of many retired professional athletes. Repeated blows to the head sustained in contact sports such asboxing and American football can result in abnormal accumulations oftau protein (usually many years later). The autopsied brains from two of these individuals are shown below.Left: courtesy of Dr. Ann McKee inNYT. Right: courtesy of Dr. Bennett Omalu inCNN. These are coronal sections1 from the autopsied brains of: (L) Aaron Hernandez, aged 27; and(R) Fred McNeill, aged 63.Part 1 of this ...
Source: The Neurocritic - Category: Neuroscience Authors: Source Type: blogs
Amyotrophic lateral sclerosis (ALS) is a devastating neurological disease, and the etiology of sporadic ALS is generally unknown. The TANK-binding kinase 1 (TBK1) gene was identified as an ALS gene contributing to a predisposition toward ALS. To reveal the frequency and characteristics of variants of the TBK1 gene in sporadic ALS patients in Japan, we analyzed the TBK1 gene by exome sequencing in a large Japanese cohort of 713 sporadic ALS patients and 800 controls. We identified known or potentially toxic rare variants of TBK1 gene in 9 patients (1.26%) with sporadic ALS, including 4 novel missense variants (p.V23I, p.H32...
Source: Neurobiology of Aging - Category: Neuroscience Authors: Source Type: research
Publication date: Available online 16 November 2017 Source:The Lancet Neurology Author(s): Ruth Chia, Adriano Chiò, Bryan J Traynor Background The disease course of amyotrophic lateral sclerosis (ALS) is rapid and, because its pathophysiology is unclear, few effective treatments are available. Genetic research aims to understand the underlying mechanisms of ALS and identify potential therapeutic targets. The first gene associated with ALS was SOD1, identified in 1993 and, by early 2014, more than 20 genes had been identified as causative of, or highly associated with, ALS. These genetic discoveries have identified ...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Authors: Matilla-Dueñas A, Corral-Juan M, Rodríguez-Palmero Seuma A, Vilas D, Ispierto L, Morais S, Sequeiros J, Alonso I, Volpini V, Serrano-Munuera C, Pintos-Morell G, Álvarez R, Sánchez I Abstract More than 600 human disorders afflict the nervous system. Of these, neurodegenerative diseases are usually characterised by onset in late adulthood, progressive clinical course, and neuronal loss with regional specificity in the central nervous system. They include Alzheimer's disease and other less frequent dementias, brain cancer, degenerative nerve diseases, encephalitis, epilepsy, geneti...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: ALS | Biotechnology | Pharmaceuticals